title: Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.
abstract: CD8+ cytotoxic T lymphocytes (CTL) against human immunodeficiency virus type 1 (HIV-1) induced by candidate HIV-1 vaccines may be a mechanism of immune protection against HIV-1 infection. We measured in vitro inducible CD8+ and CD4+ CTL using two in vitro effector cell stimulation strategies. Peripheral blood mononuclear cells (PBMC) for CTL assay were obtained after the third and/or fourth immunization timepoints from 23 healthy, uninfected adult volunteers, of whom 19 received a canarypox virus vaccine expressing HIV-1 env, gag, pol, nef and protease gene products (vCP300) with or without injections of HIV-1(SF-2) rgp120 subunit vaccine and four subjects received only control injections. CD8+ CTL activity was detected employing the two in vitro stimulation strategies against one or more HIV-1 antigens in 15 (79%) of 19 HIV-1 vaccine recipients on at least one occasion and repeatedly against the same antigen in 8 (42%). Canarypox virus-based HIV-1 vaccines represent a step forward in HIV-1 vaccine development.
authors.affiliation: St. Louis Department of Veterans Affairs Medical Center, St. Louis, MO, USA. gorsegj@slu.edu
authors.forename: G J
authors.initials: GJ
authors.lastname: Gorse
authors.forename: G B
authors.initials: GB
authors.lastname: Patel
authors.forename: M D
authors.initials: MD
authors.lastname: Mandava
authors.forename: R B
authors.initials: RB
authors.lastname: Belshe
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000328:Adult; D000818:Animals; D018150:Avipoxvirus; D016827:CD8 Antigens; D016466:CHO Cells; D006224:Cricetinae; D004359:Drug Therapy, Combination; D015686:Gene Products, env / Q000276:immunology; D015683:Gene Products, gag / Q000276:immunology; D015693:Gene Products, nef / Q000276:immunology; D015684:Gene Products, pol / Q000276:immunology; D005818:Genetic Engineering; D005822:Genetic Vectors; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology; D054311:nef Gene Products, Human Immunodeficiency Virus
chemical_list: D016915:AIDS Vaccines; C120922:ALVAC-HIV vCP300; D016827:CD8 Antigens; D015686:Gene Products, env; D015683:Gene Products, gag; D015693:Gene Products, nef; D015684:Gene Products, pol; D015699:HIV Envelope Protein gp120; C082068:HIV-1 IIIB gp120 subunit vaccine; D015395:Histocompatibility Antigens Class I; D014614:Vaccines, Synthetic; D054311:nef Gene Products, Human Immunodeficiency Virus